Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the publication of the Phase I clinical study results for its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ PD-1 inhibitor toripalimab. This combination is aimed at treating advanced solid tumors, with a particular focus on melanoma. The findings have been published in the Journal for ImmunoTherapy of Cancer.
Porustobart, developed using Harbour BioMed’s proprietary Harbour Mice platform, is a fully human anti-CTLA-4 monoclonal heavy chain-only antibody (HCAb). This innovative antibody is the first of its kind to advance to clinical trials globally. It has shown to have enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity and has demonstrated high specificity for Treg cells that highly express CTLA-4 within the tumor microenvironment. These characteristics indicate that porustobart could play a significant role in cancer immunotherapy.- Flcube.com
